Tacrolimus

Compartilhe esta página
Imprimir este artigo
Esta página foi útil?
Também chamado: FK506; TAC
[Often referred to by brand name (see MedlinePlus Drug Information)]
Nome formal: Tacrolimus
Exames relacionados: Therapeutic Drug Monitoring; Cyclosporine; BUN; Creatinine; Electrolytes; Potassium; Magnesium; Comprehensive Metabolic Panel; Glucose

De relance

Por que fazer este exame?

To determine the concentration of tacrolimus in the blood in order to establish a dosing regimen, maintain therapeutic levels, and detect toxic levels

Quando fazer este exame?

As soon as tacrolimus therapy begins, frequently at first then at regular intervals to monitor concentrations over time

Amostra:

A blood sample drawn from a vein in your arm

É necessária alguma preparação?

Have the sample collected 12 hours after the last dose and immediately prior to the next dose or as directed by your doctor.

A amostra

O que está sendo pesquisado?

This test measures the amount of tacrolimus in the blood. Tacrolimus is an immunosuppressive drug that is given orally or intravenously to patients who have had a kidney, liver, heart, or other organ transplant. Normally, a person’s immune system would recognize the new organ as foreign and begin to attack it. Tacrolimus limits this response and helps to prevent organ rejection by inhibiting the activation of T-lymphocytes.

Tacrolimus levels in the blood must be maintained within a narrow therapeutic range. If the concentration is too low, organ rejection may occur; if it is too high, then the patient may have symptoms associated with toxicity. Dosages must be tailored to the individual. Often, patients will begin with higher doses of tacrolimus at the start of therapy and then decrease the dose over the next few weeks. Tacrolimus is usually taken twice a day at set intervals before or after meals. When a person takes a dose, blood concentrations rise and peak within about 2 to 3 hours and then begin to slowly drop. The blood test is usually measured as a “trough” level. It is timed so that the collection is 12 hours post dose and/or prior to the next dose – at the drug’s lowest concentration in the blood.

Como a amostra é obtida para o exame?

A blood sample is obtained by inserting a needle into a vein in the arm.

NOTA: Se exames médicos em você ou em alguém importante para você o deixam ansioso ou constrangido, ou se você tem dificuldade de lidar com eles, leia um ou mais dos seguintes artigos: Lidando com dor, desconforto ou ansiedade durante o exame, Conselhos sobre exames de sangue, Conselhos para ajudar crianças durante exames médicos, and Conselhos para ajudar idosos durante exames médicos.

Outro artigo, Siga essa amostra, fornece uma visão da coleta e do processamento de uma amostra de sangue e de uma amostra de cultura da garganta.

É necessário algum preparo para garantir a qualidade da amostra?

Have the sample collected 12 hours after the last dose and immediately prior to the next dose or as directed by your doctor.

O exame

Como o exame é usado?

The tacrolimus test is ordered to measure the amount of drug in the blood to determine whether concentrations have reached therapeutic levels and are below toxic levels. It is important to monitor levels of tacrolimus for several reasons:

  • There is not a good correlation, as with some other medications, between the dose of tacrolimus given and level of drug in the blood.
  • Absorption and metabolism of oral doses of tacrolimus can vary greatly between patients and even in the same patient depending on the time of the dose and what, if any, food has been eaten.
  • Tacrolimus can cause kidney damage, especially in high doses. Measuring levels in patients who have had a kidney transplant may help to distinguish between kidney rejection (levels are low) and kidney damage due to tacrolimus toxicity (levels are high).

    • Tacrolimus monitoring helps ensure that each individual is receiving the right amount of drug needed to treat his or her particular case.

    ^ Voltar ao topo

    Quando o exame é pedido?

    Tacrolimus is ordered frequently at the start of therapy, often daily when trying to establish a dosing regimen. Once dosages have been established and shown to be well tolerated, then the frequency of tacrolimus testing may be decreased. The test is performed when dosages are changed and whenever patients have symptoms that suggest side effects, toxicity, or organ rejection. Monitoring at intervals is necessary as long as the patient is taking tacrolimus.

    ^ Voltar ao topo

    O que significa o resultado do exame?

    Concentrations that are higher than the established therapeutic range may cause symptoms associated with toxicity. Concentrations that are too low may lead to rejection of the transplanted organ. Side effects may be seen at any dosage but tend to be more severe with higher tacrolimus levels.

    Some signs and symptoms of tacrolimus toxicity include:

  • Kidney damage
  • Tremors
  • Headache
  • High Blood Pressure
  • Nausea and vomiting
  • Electrolyte disturbances, such as hyperkalemia
  • Tinnitus—intermittent and/or persistent ringing or roaring in the ears
  • Seizures

    • The therapeutic range established by a laboratory will depend on both the method used to measure the drug and the type of transplant. Results from different methods are not interchangeable. A doctor will usually have his patient’s samples sent consistently to the same laboratory and will be guided by that laboratory’s therapeutic ranges.

    ^ Voltar ao topo

    Há mais alguma coisa que eu devo saber?

    A variety of drugs, such as calcium channel blockers, antifungal drugs, macrolide antibiotics (such as erythromycin), protease inhibitors, chloramphenicol, and another immunosuppressant such as cyclosporine can increase tacrolimus concentrations. Drugs such as anticonvulsants (carbamazepine, phenytoin), antimicrobials (rifampin), and the immunosuppressant sirolimus can decrease tacrolimus concentrations.

    Grapefruit juice and herbal supplements such as St. John’s Wort should be avoided while taking tacrolimus.

    Tacrolimus may be given for a period of time to patients who have had bone marrow transplantation. Topical tacrolimus may be used to treat a variety of skin conditions, such as eczema, that have not responded well to other medications. This topical use of tacrolimus is intended to be local, not systemic, and is not usually monitored. In some countries, tacrolimus is also licensed for use for myasthenia gravis.

    Patients should not alter their dose or the time that they take their dose without consulting with their doctor. Tacrolimus should be taken consistently with respect to meals. Food, especially high fat meals, can significantly reduce the bioavailability (amount of the drug that reaches the circulation) compared with fasting. Women who are pregnant or planning to become pregnant should talk to their doctor about associated risks.

    ^ Voltar ao topo

    Perguntas frequentes

    1.  How long will I need to be on tacrolimus?

    Transplant patients must take tacrolimus or a different immunosuppressant (or combination of drugs) throughout their life. Talk to your doctor about the best choice for your condition. This choice may change over time.

    ^ Voltar ao topo

    2.  Who orders tacrolimus tests?

    Tacrolimus will usually be monitored by the doctor and transplant team that performed your surgery or by a doctor who has specific knowledge of the condition or disease for which the drug is prescribed.

    ^ Voltar ao topo

    3.  Should I tell my other health care providers that I am taking tacrolimus?

    Yes, this is important information for them, partially because of drug interactions and partially because of the immunosuppressive action of tacrolimus. It can affect your ability to heal, to get vaccinations, and may increase the risk of developing certain cancers (such as skin cancers).

    ^ Voltar ao topo

    Pergunte ao laboratório

    * indica um campo necessário



    Por favor, indique se você é:   
      
      



    Você deve fornecer um endereço de e-mail válido para receber uma resposta.



    | |

    Fontes do artigo

    « Voltar para páginas relacionadas

    NOTA: Este artigo se baseia em pesquisas que incluíram as fontes citadas e a experiência coletiva de Lab Tests Online Conselho de Revisão Editorial. Este artigo é submetido a revisões periódicas do Conselho Editorial, e pode ser atualizado como resultado dessas revisões. Novas fontes citadas serão adicionadas à lista e distinguidas das fontes originais usadas.

    S1
    Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry. AACC Press, Washington, DC. McMillin, G. and Hammett-Stabler, C. Chapter 39: Therapeutic Drug Monitoring, pp 453-463.

    S2
    (2007 April 1). Tacrolimus [13 paragraphs]. MedlinePlus Drug Information [On-line information]. Accessed on: 6/9/07 Available FTP: http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a601117.html

    S3
    Aradhye, S., et. al. (2006 December, Revised). Medicines for Keeping Your New Kidney Healthy [117 paragraphs]. American Society of Transplantation [On-line information]. Accessed on: 6/9/07 Available FTP: http://www.a-s-t.org/files/pdf/patient_education/english/AST-EdBroKIDNEYMED-ENG.pdf

    S4
    (2006 July 1, Revised). Tacrolimus Topical [22 paragraphs]. MedlinePlus Drug Information [On-line information]. Accessed on: 6/9/07 Available FTP: http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a602020.html

    S5
    Howard, A. (2004 July 12). Long-Term Monitoring and Care of the Kidney Transplant Recipient [6 paragraphs]. Medscape Transplantation 5(2), 2004 [On-line article]. Accessed on: 6/9/07 Available FTP: http://www.medscape.com/viewarticle/481411

    S6
    Kim, J. Cyclosporine and Tacrolimus Toxicities [5 paragraphs]. Kidney Transplant Program, Univ of Southern California Department of Surgery [On-line information]. Accessed on: 6/9/07 Available FTP: http://www.kidneytransplant.org/article-cyclosporineandtacrolimustoxicities.html

    S7
    (© 2007). Tacrolimus [8 paragraphs]. ARUP's Laboratory Test Directory [On-line information]. Accessed on: 6/16/07 Available FTP: http://www.aruplab.com/TestDirectory/clinical_guide.jsp

    S8
    (© 2007). Tacrolimus [7 paragraphs]. LabCorp's On-line Directory of Services and Interpretive Guide [On-line information]. Accessed on: 6/16/07 Available FTP: http://www.labcorp.com/datasets/labcorp/html/chapter/

    S9
    (2006 April, Revised). Prograf [139 paragraphs]. FDA MedWatch [On-line information]. Accessed on: 6/16/07 Available FTP: http://www.fda.gov/medwatch/SAFETY/2006/Apr_PIs/Prograf_PI.pdf

    S10
    (2007 April 1). Tacrolimus (Oral Route, Intravenous Route) [36 paragraphs]. Mayoclinic.com [On-line information]. Accessed on: 6/10/07 Available FTP: http://www.mayoclinic.com/health/drug-information/DR601851

    S11
    Woo, D. and James, W. (2005 May 24). Topical Tacrolimus: A Review of Its Uses in Dermatology [80 paragraphs]. Medscape from Dermatitis 2005;16(1):6-21 [On-line article]. Accessed on: 6/9/07 Available FTP: http://www.medscape.com/viewarticle/505242

    S12
    (2001). Therapeutic Drug Monitoring – Is it Important for Newer Immunosuppressive Agents? [22 paragraphs]. Medscape from Drug Ther Perspect 17(22):8-12, 2001 [On-line information]. Accessed on: 6/9/07 Available FTP: http://www.medscape.com/viewarticle/414907

    S13
    Martindale – The Complete Drug Reference. (Online information, accessed August 2007) Available FTP: http://www.thomsonhc.com/hcs/librarian/PFDefaultActionId/pf.PrintReady